Compare CAE & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAE | AMRX |
|---|---|---|
| Founded | 1947 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 6.4B |
| IPO Year | 2002 | 2018 |
| Metric | CAE | AMRX |
|---|---|---|
| Price | $27.65 | $21.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 7 |
| Target Price | ★ $32.75 | $24.29 |
| AVG Volume (30 Days) | 444.7K | ★ 3.7M |
| Earning Date | 11-11-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.29 |
| Revenue | N/A | N/A |
| Revenue This Year | $1.99 | $6.38 |
| Revenue Next Year | $0.82 | $9.21 |
| P/E Ratio | ★ $35.13 | $57.46 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.76 | $11.39 |
| 52 Week High | $34.24 | $21.68 |
| Indicator | CAE | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 71.87 | 61.46 |
| Support Level | $24.93 | $16.59 |
| Resistance Level | $28.55 | N/A |
| Average True Range (ATR) | 0.84 | 0.83 |
| MACD | 0.21 | -0.01 |
| Stochastic Oscillator | 95.77 | 93.21 |
CAE Inc provides training and aviation services, integrated enterprise solutions, in-service support, and crew-sourcing services. The company operations are managed through two segments: i) Civil Aviation: Provides comprehensive training solutions for flight, cabin, maintenance, ground personnel and air traffic controllers in commercial, business and helicopter aviation, a complete range of flight simulation training devices, ab initio pilot training and crew sourcing services, as well as airline operations digital solutions; and ii) Defense and Security which is a world-wide training and simulation provider delivering scalable, platform-independent solutions that enable and enhance force readiness and security. It generates the majority of its revenue from the Civil Aviation segment.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.